All News

USP's official standards publication, USP 25-NF 20, became official on 1 January 2002. It will now be followed by two Supplements -- one in February and one in June -- becoming official in April and August 2002.

Recall of reagent red blood cells (two notices) and advisory committee meetings

Blood Products Advisory Committee, Joint Meeting of the Transmissible Spongiform Encephalopathies Advisory Committee and the Blood Products Advisory Committee, and Vaccines and Related Biological Products Advisory Committee

New and Generic Drug Approvals [Includes Drug Label and Approval Letter] (Updated 12/27/2001)

Potency testing following nine weeks storage at room temperature found that the lots fell below the minimum potency specification.

Guidance for Industry: General Principles of Software Validation; Final Guidance for Industry and FDA Staff

Preapproval inspection of anthrax facility, new defribilator, new FDA group on safety and risk, and noodle recall.

Drug approvals for 2001 and new approvals

Guidance for Industry: Revised Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob Disease (vCJD) by Blood and Blood Products

Drug approvals

CDER News 12/10-12/11

What's New on the CBER Web Site 12/3/2001 through 12/7/2001

CBER Recall of Hepatitis A Vaccine, Inactivated (VAQTA) Packaged in single-dose prefilled syringes, posted 10 December 2001

FDA NEWS DIGEST -- December 17, 2001

Drug Approvals [Includes Drug Label and Approval Letter] (Updated 12/18/2001)

USP invites you to take a tour of its new E-newsroom

FDA final rule requiring foreign drug and biologics manufacturers to register their operations and products. Takes effect 11 Feb 2002

New and generic drug approvals

Approvals, warnings, hazards, and sentencing

The purpose of this guidance document is to inform all establishments engaged in the manufacture of Source Plasma that FDA, has approved nucleic acid tests (NAT) to identify human immundeficiency virus type 1 (HIV-1) and hepatitis C virus (HCV) in Source Plasma donations; 2) that it believes that a licensed nucleic acid test to identify HIV and HCV in Source Plasma donations, when available, should be used to adequately and appropriately reduce the risk of transmission of these communicable diseases; and 3) that it expects that a licensed nucleic acid test to identify HIV-1 and HCV in Source Plasma donations will be available after establishments submit biological license application (BLA) supplements providing for the use of an approved nucleic acid test, and after we have approved such supplements.

As of 12/04/2001CDER, Warning and Untitled Letters for 2001, new and generic drug approvals, drug approval packages, and labeling updates.

CDER News 12/03/

New information put on the CBER website this week.

FDA's news digest for events and activities at FDA during the week of 3 December 2001.

FDA's news digest for events and activities at FDA during the week of 19 November 2001